CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Primus Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Primus Therapeutics Inc
Suite 105
23 Orchard Road
Phone: (800) 903-4131p:800 903-4131 Skillman, NJ  08558  United States Fax: (302) 636-5454f:302 636-5454
Business Summary
Primus Therapeutics Inc is a United States-based pharmaceutical company. The Company seeks to develop, market and sell consumer self-care products for preventing and ameliorating the symptoms of common ailments, such as cough, cold, influenza, joint pain, and gingivitis. It also seeks to develop, market and sell products for promoting cardiovascular health. The Company focuses to sell its products under the trademarks PreVenza and Duract. Its products are based on drug delivery technologies owned by Capricorn Pharma, Inc., which is a drug development company engaged in manufacturing products using its technology. Its product range would include homeopathic remedies, dietary supplements and over-the-counter (OTC) drugs and medical foods, primarily focusing on homeopathic remedies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201012/31/2010YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Founder James D.Weir
Founder, Chief Financial Officer Michael J.Martin

General Information
Number of Employees: 2 (As of 2/10/2011)
Outstanding Shares: 7,692,308 (As of 12/31/2010)
Shareholders: 2
Federal Tax Id: 272948600
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023